PL2648726T3 - Policykliczny antagonista lpa1 i jego zastosowania - Google Patents
Policykliczny antagonista lpa1 i jego zastosowaniaInfo
- Publication number
- PL2648726T3 PL2648726T3 PL11805292T PL11805292T PL2648726T3 PL 2648726 T3 PL2648726 T3 PL 2648726T3 PL 11805292 T PL11805292 T PL 11805292T PL 11805292 T PL11805292 T PL 11805292T PL 2648726 T3 PL2648726 T3 PL 2648726T3
- Authority
- PL
- Poland
- Prior art keywords
- policyclicic
- application
- lpa1 antagonist
- lpa1
- antagonist
- Prior art date
Links
- 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 title 1
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42059910P | 2010-12-07 | 2010-12-07 | |
| EP11805292.7A EP2648726B1 (en) | 2010-12-07 | 2011-12-07 | Polycyclic lpa1 antagonist and uses thereof |
| PCT/US2011/063817 WO2012078805A1 (en) | 2010-12-07 | 2011-12-07 | Polycyclic lpa1 antagonist and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2648726T3 true PL2648726T3 (pl) | 2018-10-31 |
Family
ID=45446189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11805292T PL2648726T3 (pl) | 2010-12-07 | 2011-12-07 | Policykliczny antagonista lpa1 i jego zastosowania |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9556133B2 (pl) |
| EP (2) | EP3360552A1 (pl) |
| JP (1) | JP6030567B2 (pl) |
| KR (1) | KR101875246B1 (pl) |
| CN (2) | CN103596566B (pl) |
| AU (2) | AU2011338417B2 (pl) |
| BR (1) | BR112013013950A2 (pl) |
| CA (1) | CA2820884A1 (pl) |
| CY (1) | CY1120342T1 (pl) |
| DK (1) | DK2648726T3 (pl) |
| EA (1) | EA024967B1 (pl) |
| ES (1) | ES2674174T3 (pl) |
| HR (1) | HRP20180970T1 (pl) |
| HU (1) | HUE040397T2 (pl) |
| IL (1) | IL226698B (pl) |
| LT (1) | LT2648726T (pl) |
| MX (1) | MX347544B (pl) |
| NO (1) | NO2648726T3 (pl) |
| PL (1) | PL2648726T3 (pl) |
| PT (1) | PT2648726T (pl) |
| RS (1) | RS57377B1 (pl) |
| SG (1) | SG191041A1 (pl) |
| SI (1) | SI2648726T1 (pl) |
| SM (1) | SMT201800320T1 (pl) |
| TR (1) | TR201809293T4 (pl) |
| WO (1) | WO2012078805A1 (pl) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501136A1 (en) | 2010-12-07 | 2013-07-08 | Amira Pharmaceuticals Inc | Lysophosphatidic acid receptor antagonists and uses thereof |
| AU2012296662A1 (en) | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| ES2667798T3 (es) | 2012-12-28 | 2018-05-14 | Ube Industries, Ltd. | Compuesto heterocíclico sustituido con halógeno |
| US20140213538A1 (en) * | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| US10000459B2 (en) | 2013-03-15 | 2018-06-19 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| KR102240329B1 (ko) | 2013-06-07 | 2021-04-14 | 더 스크립스 리서치 인스티튜트 | 섬유증의 소분자 억제제 |
| WO2015066456A1 (en) | 2013-10-31 | 2015-05-07 | Bristol-Myers Squibb Company | Radioligands for imaging the lpa-1 receptor |
| AU2014358668B2 (en) * | 2013-12-04 | 2019-10-24 | Galmed Research & Development Ltd. | Aramchol salts |
| GB201410741D0 (en) * | 2014-06-17 | 2014-07-30 | Babraham Inst And University Of Birmingham The | Novel diagnostic and therapeutic method |
| AU2015281021B9 (en) | 2014-06-27 | 2019-03-28 | Ube Corporation | Salt of halogen-substituted heterocyclic compound |
| HK1252425A1 (zh) | 2015-06-05 | 2019-05-24 | Vertex Pharmaceuticals Incorporated | 用於治疗脱髓鞘疾病的三唑类药物 |
| AU2016355863A1 (en) * | 2015-11-20 | 2018-07-05 | Ube Industries, Ltd. | Pharmaceutical composition for treatment or prevention of nash |
| JP2018039755A (ja) * | 2016-09-08 | 2018-03-15 | 大塚化学株式会社 | ナトリウム２α−メチル−２β−（１，２，３−トリアゾール−１−イル）−メチルペナム−３α−カルボン酸１，１−ジオキシド一水和物結晶の製造方法 |
| JP2018039756A (ja) * | 2016-09-08 | 2018-03-15 | 大塚化学株式会社 | ナトリウム２α−メチル−２β−（１，２，３−トリアゾール−１−イル）−メチルペナム−３α−カルボン酸１，１−ジオキシド一水和物結晶の製造方法 |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| CN108318447B (zh) * | 2018-05-04 | 2020-12-18 | 山东大学 | 一种基于近红外光谱技术快速测定吡喹酮对映体组成的方法 |
| HRP20230243T1 (hr) | 2018-06-07 | 2023-04-14 | Idorsia Pharmaceuticals Ltd | Alkoksi supstituirani derivati piridinila kao antagonisti receptora lpa1 i njihova uporaba u liječenju fibroze |
| KR102224677B1 (ko) * | 2018-08-23 | 2021-03-08 | 가천대학교 산학협력단 | 티아졸로 피페라진 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물 |
| CN113366000A (zh) * | 2018-09-18 | 2021-09-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的氧杂双环酸 |
| ES2946657T3 (es) | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| AR119162A1 (es) | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| CA3160410A1 (en) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| KR102393079B1 (ko) | 2020-02-28 | 2022-04-29 | 한국화학연구원 | 가축 호흡기 질환의 예방 또는 치료용 조성물 |
| CN111608208B (zh) * | 2020-05-19 | 2022-01-11 | 浙江鲁班建材科技股份有限公司 | 一种时间可控制的吸水膨胀堵漏型预铺卷材 |
| KR102913125B1 (ko) | 2020-06-03 | 2026-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| US12383547B2 (en) | 2020-07-01 | 2025-08-12 | Vanderbilt University | Methods of treatment for a kidney disease |
| JP7819506B2 (ja) * | 2021-01-28 | 2026-02-25 | 大正製薬株式会社 | Ｌｐａ１受容体を拮抗するウレア化合物の結晶形及びそれらの製造方法 |
| CA3218917A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022241023A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240115978A (ko) | 2021-12-08 | 2024-07-26 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| KR102463504B1 (ko) | 2022-08-23 | 2022-11-04 | 주식회사 에네스지 | 원전 습분분리재열기의 종단온도차 보정 방법 |
| AU2024209233A1 (en) * | 2023-01-19 | 2025-07-31 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutically acceptable salt and crystal form of triazole compound, and preparation method therefor |
| WO2025259831A1 (en) * | 2024-06-13 | 2025-12-18 | Bristol-Myers Squibb Company | Crystal forms of a lpa1 antagonist |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| ATE420878T1 (de) * | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| AU2002353180A1 (en) | 2001-12-21 | 2003-07-15 | Avmax, Inc. | Use of ugt inhibitors to increase bioavailability |
| US20040014648A1 (en) | 2002-05-17 | 2004-01-22 | Faust Pharmaceuticals | Methods for the prevention and/or the treatment of neurological disorders |
| EP1638551B1 (en) | 2003-05-19 | 2011-12-21 | Irm Llc | Immunosuppressant compounds and compositions |
| WO2007016784A1 (en) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd. | Novel substituted 1,2,3-tπazolylmethyl-benzothiophene or -indole and their use as leukotπene biosynthesis inhibitors |
| AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| MX2008009475A (es) | 2006-01-23 | 2008-10-20 | Amira Pharmaceuticals Inc | Inhibidores triciclicos de 5-lipoxigenasa. |
| GB2466121B (en) * | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
-
2011
- 2011-12-07 SG SG2013043740A patent/SG191041A1/en unknown
- 2011-12-07 US US13/992,022 patent/US9556133B2/en active Active
- 2011-12-07 BR BR112013013950A patent/BR112013013950A2/pt not_active IP Right Cessation
- 2011-12-07 WO PCT/US2011/063817 patent/WO2012078805A1/en not_active Ceased
- 2011-12-07 ES ES11805292.7T patent/ES2674174T3/es active Active
- 2011-12-07 MX MX2013006394A patent/MX347544B/es active IP Right Grant
- 2011-12-07 PL PL11805292T patent/PL2648726T3/pl unknown
- 2011-12-07 KR KR1020137017670A patent/KR101875246B1/ko not_active Expired - Fee Related
- 2011-12-07 NO NO11805292A patent/NO2648726T3/no unknown
- 2011-12-07 AU AU2011338417A patent/AU2011338417B2/en not_active Ceased
- 2011-12-07 RS RS20180740A patent/RS57377B1/sr unknown
- 2011-12-07 HR HRP20180970TT patent/HRP20180970T1/hr unknown
- 2011-12-07 SM SM20180320T patent/SMT201800320T1/it unknown
- 2011-12-07 HU HUE11805292A patent/HUE040397T2/hu unknown
- 2011-12-07 CN CN201180066933.5A patent/CN103596566B/zh not_active Expired - Fee Related
- 2011-12-07 EP EP18163527.7A patent/EP3360552A1/en not_active Withdrawn
- 2011-12-07 JP JP2013543325A patent/JP6030567B2/ja not_active Expired - Fee Related
- 2011-12-07 CA CA2820884A patent/CA2820884A1/en not_active Abandoned
- 2011-12-07 TR TR2018/09293T patent/TR201809293T4/tr unknown
- 2011-12-07 SI SI201131465T patent/SI2648726T1/en unknown
- 2011-12-07 EA EA201390840A patent/EA024967B1/ru not_active IP Right Cessation
- 2011-12-07 CN CN201710849870.XA patent/CN107721940A/zh active Pending
- 2011-12-07 LT LTEP11805292.7T patent/LT2648726T/lt unknown
- 2011-12-07 EP EP11805292.7A patent/EP2648726B1/en active Active
- 2011-12-07 DK DK11805292.7T patent/DK2648726T3/da active
- 2011-12-07 PT PT118052927T patent/PT2648726T/pt unknown
-
2013
- 2013-06-02 IL IL226698A patent/IL226698B/en not_active IP Right Cessation
-
2016
- 2016-10-05 AU AU2016238848A patent/AU2016238848B2/en not_active Ceased
- 2016-12-16 US US15/381,562 patent/US20170121295A1/en not_active Abandoned
-
2018
- 2018-06-08 CY CY20181100603T patent/CY1120342T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2648726T3 (pl) | Policykliczny antagonista lpa1 i jego zastosowania | |
| NO2020015I1 (no) | drospirenone | |
| BR112012017441A2 (pt) | compostos e métodos | |
| ME03766B (me) | Određeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe | |
| DE112011100715T8 (de) | Hardware-hilfs-thread | |
| HRP20160737T1 (hr) | Anti-her3-protutijela i njihove uporabe | |
| PT2552242E (pt) | Resumo | |
| EP2609148A4 (en) | PHTHALIC ACID-FREE SOFT MAKER | |
| HRP20160922T1 (hr) | Oligopeptidni spojevi i njihove uporabe | |
| IL226427A0 (en) | Anti ccr4 antibodies and uses thereof | |
| IL250606A0 (en) | D2 antagonists, methods of synthesis and methods of use | |
| EP2552212A4 (en) | IMPROVED FORMULATION | |
| BR112013002544A2 (pt) | seção de armario e armario | |
| EP2531023A4 (en) | IMPROVED FORMULATION | |
| HRP20150071T1 (xx) | Agomelatin hidroklorid hidrat i njegova priprava | |
| CO6781486A2 (es) | Compuestos y su uso | |
| EP2641560A4 (en) | SURGICAL PAD | |
| DE112011101333A5 (de) | Parkouraufbau | |
| DK2468677T3 (da) | Stablekran | |
| EP2647648A4 (en) | hydroxyalkylcellulose | |
| IT1398438B1 (it) | Dispositivo di premacinazione e relativo procedimento | |
| DE11786796T8 (de) | Antigenpeptid und verwendung davon | |
| BR112012029669A2 (pt) | composição e método | |
| FR2964937B1 (fr) | Triporteur et direction de triporteur | |
| IT1399740B1 (it) | Cerniera bloccante |